Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMAPALUMAB Cause Dermatitis exfoliative generalised? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Dermatitis exfoliative generalised have been filed in association with EMAPALUMAB (GAMIFANT). This represents 5.2% of all adverse event reports for EMAPALUMAB.

9
Reports of Dermatitis exfoliative generalised with EMAPALUMAB
5.2%
of all EMAPALUMAB reports
0
Deaths
9
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From EMAPALUMAB?

Of the 9 reports, 9 (100.0%) required hospitalization.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMAPALUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does EMAPALUMAB Cause?

Off label use (67) Condition aggravated (37) Drug ineffective (37) Haemophagocytic lymphohistiocytosis (33) Multiple organ dysfunction syndrome (22) Staphylococcal bacteraemia (17) Adrenal insufficiency (14) Drug reaction with eosinophilia and systemic symptoms (14) Respiratory failure (14) Pyrexia (12)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) DUPILUMAB (162) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) SECUKINUMAB (96) VANCOMYCIN (92) AMLODIPINE (91)

Which EMAPALUMAB Alternatives Have Lower Dermatitis exfoliative generalised Risk?

EMAPALUMAB vs EMAPALUMAB-LZSG EMAPALUMAB vs EMEND EMAPALUMAB vs EMICIZUMAB EMAPALUMAB vs EMICIZUMAB-KXWH EMAPALUMAB vs EMPAGLIFLOZIN

Related Pages

EMAPALUMAB Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised EMAPALUMAB Demographics